Patents by Inventor Gerald Krystal

Gerald Krystal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8956824
    Abstract: This invention provides a method for identifying allosteric modulators of a SHIP polypeptide, wherein said SHIP polypeptide is contacted with a test compound, and wherein said SHIP polypeptide comprises an allosteric site selected from the group consisting of a SHIP C2 domain and a SHIP PH domain.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: February 17, 2015
    Assignee: British Columbia Cancer Agency Branch
    Inventors: Alice Mui, Christopher Ong, Gerald Krystal, Raymond Andersen
  • Patent number: 8765994
    Abstract: The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: July 1, 2014
    Assignee: The University of British Columbia
    Inventors: Raymond Andersen, David E. Williams, Alice Mui, Christopher Ong, Gerald Krystal, Lu Yang
  • Publication number: 20120129925
    Abstract: The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.
    Type: Application
    Filed: August 19, 2011
    Publication date: May 24, 2012
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Raymond Andersen, David E. Williams, Alice Mui, Christopher Ong, Gerald Krystal, Lu Yang
  • Publication number: 20100311094
    Abstract: This invention provides a method for identifying allosteric modulators of a SHIP polypeptide, wherein said SHIP polypeptide is contacted with a test compound, and wherein said SHIP polypeptide comprises an allosteric site selected from the group consisting of a SHIP C2 domain and a SHIP PH domain.
    Type: Application
    Filed: June 4, 2009
    Publication date: December 9, 2010
    Inventors: Alice Mui, Christopher Ong, Gerald Krystal, Raymond Andersen
  • Publication number: 20100099737
    Abstract: The invention provides, in part, compositions and methods for protecting a hemopoietic cell, or for treating myelosuppression, in a subject in need thereof, by administering an effective amount of an inhibitor of a SH2-containing inositol-5?-phosphatase.
    Type: Application
    Filed: August 24, 2007
    Publication date: April 22, 2010
    Inventors: Gerald Krystal, Christopher Ong, Alice Mui
  • Publication number: 20080090909
    Abstract: The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.
    Type: Application
    Filed: October 11, 2007
    Publication date: April 17, 2008
    Inventors: Raymond Andersen, David Williams, Alice Mui, Christopher Ong, Gerald Krystal, Lu Yang
  • Patent number: 7115562
    Abstract: The present invention relates to a method of reducing cell death in a warm-blood animal wherein said cell death associated with a neurodegenerative disorder, an immune disease, a neoplastic disorder, an inflammatory disorder, or a viral disease. The method comprises administering to said animal a therapeutically effective amount of a peptide comprising amino acid sequence: Ser-Val-Asp-Val-Glu-Tyr.
    Type: Grant
    Filed: January 11, 2005
    Date of Patent: October 3, 2006
    Assignee: CV Molecular Therapeutics, Inc.
    Inventors: Gerald Krystal, Simon W. Rabkin
  • Publication number: 20050282741
    Abstract: There is disclosed novel peptides, fragments or analogues thereof and polynucleotides encoding the same, obtained from streptokinase suitable for use in the amelioration of cell death and methods related thereto.
    Type: Application
    Filed: January 11, 2005
    Publication date: December 22, 2005
    Inventors: Gerald Krystal, Simon Rabkin
  • Patent number: 6841532
    Abstract: There is disclosed novel peptides, fragments or analogues thereof and polynucleotides encoding the same, obtained from streptokinase suitable for use in the amelioration of cell death and methods related thereto.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: January 11, 2005
    Assignee: CV Molecular Therapeutics, Inc.
    Inventors: Gerald Krystal, Simon W. Rabkin
  • Publication number: 20040266865
    Abstract: The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.
    Type: Application
    Filed: April 16, 2004
    Publication date: December 30, 2004
    Inventors: Raymond Andersen, David E. Williams, Alice Mui, Christopher Ong, Gerald Krystal
  • Publication number: 20020165129
    Abstract: There is disclosed novel peptides, fragments or analogues thereof and polynucleotides encoding the same, obtained from streptokinase suitable for use in the amelioration of cell death and methods related thereto.
    Type: Application
    Filed: July 31, 2001
    Publication date: November 7, 2002
    Inventors: Gerald Krystal, Simon W. Rabkin
  • Patent number: 6348567
    Abstract: There is disclosed novel peptides, fragments or analogues thereof and polynucleotides encoding the same, obtained from streptokinase suitable for use in the amelioration of cell death and methods related thereto.
    Type: Grant
    Filed: April 19, 1999
    Date of Patent: February 19, 2002
    Assignee: CV Molecular Therapeutics Inc.
    Inventors: Gerald Krystal, Simon W. Rabkin
  • Patent number: 6238903
    Abstract: Novel SH2-containing inositol-phosphatase which has a src homology 2 (SH2) domain and exhibits phosphoIns-5-ptase activity, and nucleic acid molecules encoding the novel protein are disclosed. The invention also relates to methods for identifying substances which affect the binding of the protein to Shc and/or its phosphoIns-5-ptase activity and methods for screening for agonists or antagonists of the binding of the protein and Shc.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: May 29, 2001
    Inventor: Gerald Krystal
  • Patent number: 6218162
    Abstract: Novel SH2-containing inositol-phosphatase which has a src homology 2 (SH2) domain and exhibits phosphoIns-5-ptase activity, and nucleic acid molecules encoding the novel protein are disclosed. The invention also relates to methods for identifying substances which affect the binding of the protein to Shc and/or its phosphoIns-5-ptase activity and methods for screening for agonists or antagonists of the binding of the protein and Shc.
    Type: Grant
    Filed: June 14, 1996
    Date of Patent: April 17, 2001
    Inventor: Gerald Krystal
  • Patent number: 5917013
    Abstract: There is disclosed novel peptides, fragments or analogues thereof and polynucleotides encoding the same, derived from streptokinase suitable for use in the amelioration of cell death and methods related thereto.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: June 29, 1999
    Assignee: Simon W. Rabkin
    Inventors: Simon W. Rabkin, Gerald Krystal
  • Patent number: 4554254
    Abstract: A novel, inexpensive, highly sensitive and quantitative assay for measuring protein in solution based on the capacity of protein to bind silver is described. In this procedure, protein samples are first treated with glutaraldehyde and then exposed to ammoniacal silver. After a specified time, the reaction is terminated by the addition of sodium thiosulfate and the optical density measured at 420 nm. The useful range of the assay for the majority of standard proteins tested lies between 15 and 2000 ng. This represents a 100-fold increase in sensitivity over the Coomassie Brilliant Blue dye binding procedure. There is little or no interference from carbohydrates, non-ionic detergents or ethanol. Pretreatment of protein samples with Bio-Gel P-2 to remove salts, thiol agents, EDTA and SDS, makes this procedure compatible with most commonly used buffers.
    Type: Grant
    Filed: December 17, 1984
    Date of Patent: November 19, 1985
    Inventor: Gerald Krystal